OUR Portfolio
Tullis-Dickerson Capital Focus III, L.P.

			Adams Respiratory Therapeutics, Inc. Adams is a specialty pharmaceutical company focused on late stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders. Adams was acquired by Reckitt Benckiser in January 2008.

			Adiana, Inc. Adiana is developing a permanent non-incisional contraceptive device for women. Adiana was acquired by Cytyc Corporation in March 2007.

			Aldagen, Inc. Aldagen has developed a proprietary technology to isolate adult stem cells that express high levels of ALDH, referred to as ALDH-bright, or ALDHbr, cells.

			Atritech, Inc. Atritech is a medical device company developing a novel implantable system to prevent stroke in patients with atrial fibrillation.

			BioBehavioral Diagnostics Company BioBDx develops diagnostic systems that aid clinicians in the objective assessment of behavioral and neurobiological disorders. The company's lead product, the Quotient ADHD System, is the first FDA-cleared test that offers medical professionals an office-based capability to conduct rapid, precise and objective patient assessments to aid in the diagnosis of ADHD.

			BioRexis Pharmaceutical Corporation BioRexis develops novel, long-acting versions of known biopharmaceuticals using a proprietary protein engineering technology. The company's products can also be produced in highly efficient, yeast-based manufacturing systems. BioRexis was acquired by Pfizer in February 2007.

			Ikano Therapeutics, Inc. Ikano Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need.

			Impulse Monitoring, Inc. Impulse Monitoring provides intra-operative neurological monitoring during invasive surgical procedures, particularly in spinal and cranial surgery.